Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ICU, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
ICU holds $4M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.2M/quarter from operations, an estimated runway of 3.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 70 · High
The Company believes that these conditions raise substantial doubt about its ability to continue as a going concern.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ICU files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Mitchell P. Kopin | Institution (13G, 5%+) | 489,105 | 9.20% | 2026-09-30 |
| Ayrton Capital LLC | Institution (13G, 5%+) | 278,436 | 5.24% | 2026-03-31 |
| LPL Financial LLC | Institution (13F) | 66,801 | 1.26% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 51,009 | 0.96% | 2026-09-30 |
| Eric Schlorff Chief Executive Officer |
Insider | 50,140 | 0.94% | 2026-07-01 |
| Vanguard Capital Management LLC | Institution (13F) | 33,091 | 0.62% | 2026-09-30 |
| Kevin Chung Chief Medical Officer |
Insider | 28,021 | 0.53% | 2026-07-01 |
| UBS Group AG | Institution (13F) | 26,614 | 0.50% | 2026-09-30 |
| John Neuman Director |
Insider | 16,200 | 0.30% | 2026-07-01 |
| Vanguard Fiduciary Trust Co | Institution (13F) | 13,692 | 0.26% | 2026-09-30 |
| HRT Financial LP | Institution (13F) | 12,579 | 0.24% | 2026-09-30 |
| Heel Kenneth Van Director |
Insider | 11,940 | 0.22% | 2026-07-01 |
Share count 5,315,967 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-18 filed 2026-08-19 |
Messinger Michael |
Purchase (P) | 750 | $3.27 | 2,500 |
| 2026-07-01 filed 2026-07-02 |
Schlorff Eric |
Award (A) | 10,288 | – | 50,140 |
| 2026-07-01 filed 2026-07-02 |
Chung Kevin |
Award (A) | 7,202 | – | 28,021 |
| 2026-07-01 filed 2026-07-02 |
Vincent Bernadette N |
Award (A) | 4,000 | – | 8,200 |
| 2026-07-01 filed 2026-07-02 |
Neuman John |
Award (A) | 4,000 | – | 16,200 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ICU and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →